Serum transthyretin levels and disease activity in patients with primary Sjögren's syndrome.

IF 3.4 2区医学 Q2 RHEUMATOLOGY

Therapeutic Advances in Musculoskeletal Disease Pub Date : 2024-10-16 eCollection Date: 2024-01-01 DOI:10.1177/1759720X241283528

You-Fan Peng, Fei-Yan Lu, Yi-Bin Deng

{"title":"Serum transthyretin levels and disease activity in patients with primary Sjögren's syndrome.","authors":"You-Fan Peng, Fei-Yan Lu, Yi-Bin Deng","doi":"10.1177/1759720X241283528","DOIUrl":null,"url":null,"abstract":"Background: A strong association has been demonstrated between serum transthyretin (TTR) levels and autoimmune diseases. However, there is limited information regarding the role of serum TTR in patients with primary Sjögren's syndrome (pSS).Objectives: This study was designed to explore the association between serum TTR and disease activity in patients with pSS.Design: This study was a retrospective observational study.Methods: This study included 84 patients with pSS and 135 age- and sex-matched healthy controls retrospectively, and collected data were analyzed. The European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI) and Clinical ESSDAI (ClinESSDAI) scores were used to assess the disease activity in patients with pSS.Results: Serum TTR levels were significantly lower in patients with pSS than those in healthy controls (181.9 ± 69.2 vs 241.8 ± 48.9 mg/L, p < 0.001). Serum TTR levels were significantly and negatively correlated with ESSDAI (r = -0.385, p < 0.001) and ClinESSDAI (r = -0.340, p = 0.002) scores in patients with pSS, respectively. Multivariable linear regression analysis showed that serum TTR was significantly associated with ESSDAI (Beta = -0.248, p = 0.017) and ClinESSDAI (Beta = -0.215, p = 0.036) scores in patients with pSS, respectively.Conclusion: Serum TTR is a potential marker for assessing disease activity in patients with pSS, which may contribute to the clinical management of pSS.","PeriodicalId":23056,"journal":{"name":"Therapeutic Advances in Musculoskeletal Disease","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11483703/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Musculoskeletal Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/1759720X241283528","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: A strong association has been demonstrated between serum transthyretin (TTR) levels and autoimmune diseases. However, there is limited information regarding the role of serum TTR in patients with primary Sjögren's syndrome (pSS).

Objectives: This study was designed to explore the association between serum TTR and disease activity in patients with pSS.

Design: This study was a retrospective observational study.

Methods: This study included 84 patients with pSS and 135 age- and sex-matched healthy controls retrospectively, and collected data were analyzed. The European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI) and Clinical ESSDAI (ClinESSDAI) scores were used to assess the disease activity in patients with pSS.

Results: Serum TTR levels were significantly lower in patients with pSS than those in healthy controls (181.9 ± 69.2 vs 241.8 ± 48.9 mg/L, p < 0.001). Serum TTR levels were significantly and negatively correlated with ESSDAI (r = -0.385, p < 0.001) and ClinESSDAI (r = -0.340, p = 0.002) scores in patients with pSS, respectively. Multivariable linear regression analysis showed that serum TTR was significantly associated with ESSDAI (Beta = -0.248, p = 0.017) and ClinESSDAI (Beta = -0.215, p = 0.036) scores in patients with pSS, respectively.

Conclusion: Serum TTR is a potential marker for assessing disease activity in patients with pSS, which may contribute to the clinical management of pSS.

查看原文本刊更多论文

原发性斯约格伦综合征患者的血清转甲状腺素水平和疾病活动性。

背景：血清转甲状腺素（TTR）水平与自身免疫性疾病之间存在密切联系。然而，有关血清 TTR 在原发性斯约格伦综合征（pSS）患者中的作用的信息却很有限：本研究旨在探讨原发性斯约格伦综合征（pSS）患者血清 TTR 与疾病活动性之间的关系：本研究是一项回顾性观察研究：本研究回顾性纳入了 84 名 pSS 患者和 135 名年龄和性别匹配的健康对照者，并对收集的数据进行了分析。采用欧洲抗风湿病联盟（EULAR）的斯约格伦综合征疾病活动指数（ESSDAI）和临床ESSDAI（ClinESSDAI）评分来评估pSS患者的疾病活动性：pSS患者血清TTR水平明显低于健康对照组（181.9 ± 69.2 vs 241.8 ± 48.9 mg/L，p r = -0.385，p r = -0.340，p = 0.002）。多变量线性回归分析显示，血清TTR分别与pSS患者的ESSDAI（Beta = -0.248，p = 0.017）和ClinESSDAI（Beta = -0.215，p = 0.036）评分显著相关：血清 TTR 是评估 pSS 患者疾病活动性的潜在标志物，可能有助于 pSS 的临床治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Therapeutic Advances in Musculoskeletal Disease Medicine-Rheumatology

CiteScore

6.80

自引率

4.80%

发文量

132

审稿时长

18 weeks

期刊介绍： Therapeutic Advances in Musculoskeletal Disease delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of musculoskeletal disease.